I believe the "dud" in question is not that it won't be approved, but that it won't matter if it IS approved because cervical cancer is too small an indication.
People talking about Axal having no chance for approval have not the first clue what they're talking about. The better metaconversation is in discussing how strong the chances are. Dew and I had a back-and-forth about the differences in strength of evidence that Merck has with their pembro application for approval in PRmCC with the FDA.
News 
Market Data 
Discover 
